Report error Found 40 Enz. Inhib. hit(s) with all data for entry = 12408
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0250nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0320nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0400nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0400nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0400nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0500nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.102nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.102nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.102nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.112nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.120nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.120nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.126nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.158nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.174nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.295nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.324nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.372nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.389nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.427nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.447nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.457nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.550nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.603nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.603nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.631nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 1nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 1.07nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 1.12nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 1.20nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 1.91nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 2.09nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 2.40nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 3.55nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
